Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04730544 |
TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE ) | Phase
Phase 2
|
Date Added 2021-01-29 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT04724239 |
TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | Phase
Phase 2
|
Date Added 2021-01-26 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
chidamide, IBI305, Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04708470 |
TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | Phase
Phase 1, Phase 2
|
Date Added 2021-01-14 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bintrafusp alfa, Entinostat, NHS-IL12 |
Tags
MSS/ MMRp
|
| NCT ID NCT04687631 |
TitleConversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | Phase
Phase 3
|
Date Added 2020-12-29 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04660812 |
TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Phase
Phase 1, Phase 2
|
Date Added 2020-12-09 |
Location
Alabama, United States
Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy Korea, Republic of Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04659382 |
TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-12-09 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, TheraSphere, XELOX |
Tags
MSS/ MMRp
|
| NCT ID NCT04653480 |
TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | Phase
Phase 2
|
Date Added 2020-12-04 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy, Surufatinib, Toripalimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04626635 |
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2020-11-12 |
Location
California, United States
Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
cemiplimab, REGN7075 |
Tags
MSS/ MMRp
|
| NCT ID NCT04607421 |
TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) | Phase
Phase 3
|
Date Added 2020-10-29 |
Location
Arizona, United States
California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT04599140 |
TitleSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | Phase
Phase 1
|
Date Added 2020-10-22 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CXCR1/2 Inhibitor SX-682, Nivolumab |
Tags
MSS/ MMRp
|
